Lv6
2320 积分 2025-02-26 加入
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
11天前
已完结
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
1个月前
已完结
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
1个月前
已完结
新型FAP靶向示踪剂64Cu-FAPI-XT117在恶性实体肿瘤中的初步临床研究：与18F-FDG的对比研究
3个月前
已完结
Experimental-histological studies on the labyrinth; supplementary remarks concerning the phenomena of compression observed on intravital and postmortal fixation
3个月前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
3个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
3个月前
已完结
Trends in clinical success rates and therapeutic focus
4个月前
已完结
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
4个月前
已完结
Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA
5个月前
已完结
皖公网安备34019202002308
